GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO ...

GEO-MVA Provides Potential Opportunity to Expand Mpox Vaccine Supply Amid Growing U.S. and Global Clade 1 Threat ATLANTA, GA ...

Preclinical Studies Demonstrate Durable Protection Against SARS-CoV-2 Variants, Including Omicron XBB.1.5, Driven by T-Cell Responses  ATLANTA, GA - June 9, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc.

Highlights Broad National Support for Domestic Vaccine Resilience and Role of MVA Platform in Public Health Preparedness  ATLANTA, GA - May 29, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), ...

Our GeoVax Labs Inc consensus estimates page is based on consensus analyst forecast, covering public companies earnings per share and revenue. You'll be provided with GeoVax Labs overall consensus ...

ATLANTA, GA - May 27, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced its ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon and welcome everyone to the GeoVax Third Quarter 2024 Corporate Update Call. My name is ...

ATLANTA, GA - May 20, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer ...

John N. Spencer Jr., a director at GeoVax Labs, Inc. (NASDAQ:GOVX), recently purchased 10,000 shares of the company's common... GeoVax Labs, Inc. (NASDAQ:GOVX) President and CEO, David A. Dodd, has ...